Key takeaways:
Jardiance (empagliflozin) and Entresto (sacubitril/valsartan) are currently the only medications FDA-approved to treat heart failure with preserved ejection fraction (HFpEF).
Both Jardiance and Entresto lower the risk of HFpEF hospitalizations and deaths. But recent guidelines suggest Jardiance may be preferred.
There are many ways to save on Jardiance and Entresto. If you’re eligible, manufacturer savings cards can help make your prescription more affordable. Patient assistance programs are also available.
Heart failure is a condition that happens when the heart doesn’t effectively pump blood to the body. It affects over 6 million adults in the U.S. and can be difficult to treat. Usually, people with heart failure have to take several medications to stop their condition from getting worse.
The two most common types of heart failure are heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Many medications are used to treat HFrEF, including angiotensin-converting enzyme (ACE) inhibitors and beta blockers. However, HFpEF historically has not had as many FDA-approved treatments available — until recently.
In the past two years, the FDA approved Jardiance (empagliflozin) and Entresto (sacubitril/valsartan) to treat heart failure more broadly, focusing on HFpEF. Here, we’ll review these two medications and how they help treat HFpEF.
Jardiance belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. Jardiance mainly works in the kidney by stopping you from absorbing sugar, causing you to urinate it out instead.
Jardiance was originally approved to treat Type 2 diabetes. However, research found that it could also be used for other health problems, like protecting the kidneys or the heart.
Currently, Jardiance is FDA-approved to:
Treat Type 2 diabetes along with a healthy diet and exercise
Lower the risk of heart-related death in people with Type 2 diabetes and heart disease
Lower the risk of death and hospital stays due to HFrEF or HFpEF
It’s believed Jardiance may work for HFpEF in several ways:
By removing fluid and sodium from the body
By stopping the heart from changing shape over time
By lowering the amount of heart inflammation (swelling)
By lowering blood pressure
By helping the heart to pump more effectively
Experts continue to study Jardiance to find out if it helps treat heart failure in any other ways.
Entresto is a combination of two medications: sacubitril and valsartan. Sacubitril is an angiotensin receptor neprilysin inhibitor (ARNI). It’s currently the only FDA-approved ARNI and is only found in Entresto. Valsartan is an angiotensin II receptor blocker (ARB). Valsartan is available by itself, marketed under the brand name Diovan and as a generic.
Entresto is FDA-approved to treat heart failure in both adults and children. For adults with heart failure, it can be prescribed for either HFrEF or HFpEF. But it’s most beneficial for people with an ejection fraction (EF) that’s below normal or on the lower side of normal.
An EF is a measurement that represents how much blood your heart is pumping out to your body. An EF between 50% and 70% is considered normal. People with HFrEF have an EF under 40%. People with HFpEF have an EF that’s at least 40%, but they may have a normal EF.
The medications in Entresto work together to help the heart pump better. They relax the blood vessels and help prevent fluid from building up, which causes many heart failure complications.
Entresto also helps stop the body from making certain chemicals that are thought to cause the heart to change shape over time. These shape changes make the heart muscle stiff and pump less efficiently.
Jardiance and Entresto are both tablets that you take by mouth. But, they’re a little different in how they are taken.
Jardiance is taken once a day in the morning with or without food. It comes available as 10 mg and 25 mg tablets, but you only need to take 10 mg for heart failure. The higher strength is only recommended when treating diabetes.
Entresto comes in three different strengths. Most people start with the 49 mg/51 mg strength twice daily. Your healthcare provider may raise your dose a few weeks later, depending on how you respond. If you’ve been taking an ACE inhibitor, like lisinopril, you’ll need to stop taking it for a few days before starting Entresto.
Both Entresto and Jardiance are FDA-approved for HFrEF and HFpEF. But, there are questions about which is better for HFpEF. It’s important to note that Entresto and Jardiance haven’t been directly compared to each other in clinical trials yet.
In studies, Jardiance lowered the number of HFpEF-related hospitalizations and deaths. A similar benefit was seen for all study participants taking Jardiance, regardless of their EF. This clinical trial compared Jardiance to placebo (a pill with no medication in it).
In a different clinical trial, Entresto was compared to valsartan (one of the two ingredients in Entresto). Entresto helped lower the number of HFpEF hospitalizations and deaths compared to valsartan. But, these results weren’t statistically significant for all study participants.
Entresto helped some people with HFpEF more than others. Entresto had the best effects for people with an EF between 45% and 57% and for women. So not all people with HFpEF may benefit from Entresto.
Recently, experts released new guidelines for treating HFpEF. Currently, both Entresto and Jardiance can be used to treat the condition. However, recent studies suggest that medications like Jardiance may have more evidence to support their use over Entresto. But Jardiance may not be right for everyone. Your healthcare provider can help you understand why they chose one over the other for you.
Since Jardiance and Entresto are from different classes of medications, they have different side effects.
Jardiance’s common side effects include urinary tract infections (UTIs) and yeast infections. Less commonly, it can cause low blood sugar, dehydration, and kidney damage. Jardiance isn’t recommended for people with severe kidney problems or those on dialysis.
Entresto’s common side effects include:
Low blood pressure
Cough
Dizziness
Kidney problems
Entresto can also cause swelling of the face, lips, and neck. This is called angioedema, and it can be life-threatening. If you’ve experienced angioedema with ACE inhibitors or ARBs before, you shouldn’t take Entresto. This medication should also be avoided if you’re pregnant, as it’s known to harm unborn babies.
Jardiance can interact with other diabetes medications, raising your risk of severely low blood sugar. It also interacts with diuretics (water pills), making dehydration more likely. It’s important to know that Jardiance can be combined with these other medications if needed. But caution should be taken to help prevent problems.
Entresto interacts with the following:
ACE inhibitors, such as enalapril (Vasotec)
ARBs, such as losartan (Cozaar)
Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen (Advil, Motrin)
Potassium-sparing diuretics, such as spironolactone (Aldactone)
These may not be the only interactions for Jardiance and Entresto. It’s important to share an updated medication list with your pharmacist and healthcare provider. They’ll review this list and make sure it’s safe for you to take them.
Jardiance and Entresto are only available as brand-name medications. But GoodRx can help you navigate ways to save on your prescription.
Save with patient assistance programs. If you’re uninsured or underinsured, you may be eligible for the Jardiance or Entresto patient assistance programs, which offer the medications at no charge.
Save with a copay savings card. If you have commercial insurance and meet eligibility requirements, Jardiance’s price is as little as $10 if you use the manufacturer’s savings card. Entresto’s price is also as little as $10 if you use the manufacturer’s savings card.
Yes, you can take Jardiance and Entresto together. Current guidelines recommend combining them to treat HFrEF in some cases. In the HFpEF studies discussed earlier, some people were taking both. Whether you should be on both varies and is a decision best made with your healthcare provider.
After several decades of few options to treat HFpEF, recent years have provided two new treatment options: Entresto and Jardiance. The medications work differently to treat heart failure, but both have benefits. They each have different side effects and reasons people shouldn’t take them. This can impact which one your healthcare provider may recommend for you.
American Heart Association. (2017). Ejection fraction heart failure measurement.
American Heart Association. (2017). Types of heart failure.
Anker, S. D., et al. (2021). Empagliflozin in heart failure with a preserved ejection fraction. The New England Journal of Medicine.
Boehringer Ingelheim Pharmaceuticals, Inc. (2022). Jardiance [package insert].
Boehringer Ingelheim Pharmaceuticals, Inc. (2022). US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction.
Centers for Disease Control and Prevention. (2020). Heart failure.
Clegg, L. E., et al. (2019). Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: An analysis of the placebo arm of EXSCEL. Diabetes Care.
Heidenreich, P. A., et al. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation.
Lopaschuk, G. D., et al. (2020). Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC: Basic to Translational Science.
Maddox, T. M., et al. (2021). 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology solution set oversight committee. Journal of the American College of Cardiology.
Novartis Pharmaceuticals Corporation. (2021). Entresto [package insert].
Solomon, S. D., et al. (2019). Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. The New England Journal of Medicine.
Wang, Y., et al. (2019). Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: Meta-analysis. Journal of the American Heart Association.